Status:
COMPLETED
Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Eligibility:
All Genders
20-80 years
Brief Summary
The purpose of this observational study is to survey the safety and effectiveness of the product under the real condition of usual practice in Taiwanese hypertensive patients. During the 8-week observ...
Eligibility Criteria
Inclusion
- 1\. Male or female. 2. Aged 20 to 80 years old. 3. Patients meet one of following two criteria:
- Adult essential hypertensive either newly diagnosed and untreated, or previously treated and uncontrolled patients; sitting blood pressure: systolic blood pressure (BP) \> 140 mmHg but \< 180 mmHg, and/or diastolic BP \> 90 mmHg but \< 110 mmHg).
- Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication.
Exclusion
- Patients with contraindications to telmisartan use (as per the Micardis® Tablets package insert).
- Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® Tablets.
- Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.
Key Trial Info
Start Date :
December 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
3148 Patients enrolled
Trial Details
Trial ID
NCT00615108
Start Date
December 1 2006
Last Update
April 7 2014
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigator Site
Changhua, Taiwan
2
Boehringer Ingelheim Investigator Site 1
Chiayi City, Taiwan
3
Boehringer Ingelheim Investigator Site 2
Chiayi City, Taiwan
4
Boehringer Ingelheim Investigator Site
Keelung, Taiwan